Key facts
- It has raised $13.0M across 1 recorded rounds; the latest was Early Stage VC ($13.0M) in Apr 2026.
- Notable investors include National Institutes of Health, U.S. Department of Health and Human Services, Zynext Ventures.
- Illexcor Therapeutics has filed 1 Form D with the SEC, most recently May 2026 ($13.0M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Illexcor Therapeutics
Funding rounds
1 roundsAbout Illexcor Therapeutics
Operator of a biopharmaceutical company intended for the discovery and development of innovative oral therapies for sickle cell disease. The company develops oral Hemoglobin S polymerization inhibitors that can provide profound disease-modifying clinical benefits for sickle cell disease, enabling patients living with hematologic diseases to improve their lives and provide effective and disease-modifying treatments.
- Sector
- Healthcare
- HQ
- Richmond, VA, United States
- Founded
- 2020
- Employees
- 6
- Website
- illexcor.com/
- Ownership
- Privately Held (backing)
Illexcor Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Illexcor Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Illexcor Therapeutics in its N-PORT filings yet. We sweep new filings monthly.